Analyst Price Targets — IART
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 15, 2026 12:28 pm | Richard Newitter | Truist Financial | $12.00 | $11.01 | TheFly | Integra LifeSciences price target lowered to $12 from $13 at Truist |
| October 15, 2025 12:34 pm | — | Truist Financial | $15.00 | $14.76 | TheFly | Integra LifeSciences price target raised to $15 from $13 at Truist |
| October 7, 2024 5:33 am | Ryan Zimmerman | BTIG | $20.00 | $17.43 | StreetInsider | BTIG Upgrades Integra LifeSciences (IART) to Neutral |
| July 30, 2024 8:59 am | Richard Newitter | Truist Financial | $26.00 | $24.59 | TheFly | Integra LifeSciences price target lowered to $26 from $32 at Truist |
| July 30, 2024 3:24 am | Joanne Wuensch | Citigroup | $23.00 | $25.42 | StreetInsider | Citi Downgrades Integra LifeSciences (IART) to Sell |
| July 29, 2024 4:12 pm | Ryan Zimmerman | BTIG | $22.00 | $25.42 | TheFly | Integra LifeSciences downgraded to Sell from Neutral at BTIG |
| July 16, 2024 7:33 am | Richard Newitter | Truist Financial | $32.00 | $29.84 | TheFly | Integra LifeSciences price target raised to $32 from $25 at Truist |
| May 7, 2024 7:16 am | Richard Newitter | Truist Financial | $25.00 | $23.14 | StreetInsider | Integra LifeSciences (IART) PT Lowered to $25 at Truist Securities |
| May 7, 2024 6:56 am | David Turkaly | JMP Securities | $40.00 | $23.14 | TheFly | Integra LifeSciences price target lowered to $40 from $49 at JMP Securities |
| May 6, 2024 4:15 pm | Vik Chopra | Wells Fargo | $25.00 | $23.14 | StreetInsider | Wells Fargo Downgrades Integra LifeSciences (IART) to Equal Weight |
Latest News for IART
PRINCETON, N.J., April 20, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will release first quarter 2026 financial results on Tuesday, May 5, 2026, prior to the market open. In conjunction with the earnings release, Integra's management team will host a conference call at 8:30 a.m. ET.
Integra (IART) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Integra LifeSciences Holdings Corporation (NASDAQ: IART - Get Free Report) gapped down before the market opened on Wednesday after Truist Financial lowered their price target on the stock from $13.00 to $12.00. The stock had previously closed at $11.06, but opened at $10.60. Truist Financial currently has a hold rating on the stock. Integra LifeSciences shares
Results to be featured at Functional Diabetic Limb Salvage, Society of Advanced Wound Care and American Burn Association Conferences in April Results to be featured at Functional Diabetic Limb Salvage, Society of Advanced Wound Care and American Burn Association Conferences in April
Sartorius (OTCMKTS:SARTF - Get Free Report) and Integra LifeSciences (NASDAQ: IART - Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, dividends, valuation, profitability, risk, earnings and institutional ownership. Insider and Institutional Ownership 84.8% of Integra LifeSciences shares
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.